Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma.

Histopathology - 1 Aug 2018

Mehrad Mitra, Roy Somak, LaFramboise William A, Petrosko Patti, Miller Caitlyn, Incharoen Pimpin, Dacic Sanja

Abstract excerpt

AIMS: Pulmonary sarcomatoid carcinoma (PSC) is a poorly differentiated non-small-cell lung carcinoma (NSCLC) with aggressive behaviour. This study aimed to evaluate the prognostic clinicopathological and genetic characteristics of PSCs. METHODS AND RESULTS: Fifty-three cases of surgically treated PSCs were selected, 23 of which were subjected to mutation and copy number variation analysis using the 50-gene Ion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to JAK3 gene

Share to Kaplan-Meier Estimate

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 29489023
DOI: 10.1111/his.13505
PMCID: PMC7393997

Genes

KRAS
MET
ATM
EGFR
AKT1
HRAS
JAK3
KIT
PDGFRA
SMAD4
STK11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma.PMID 29489023Read ↗

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.Semantic proximity Read ↗

Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.Semantic proximity Read ↗

Analysis of molecular pathologic and clinical features of 36 patients with pulmonary sarcomatoid carcinoma.Semantic proximity Read ↗

Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases.Semantic proximity Read ↗

Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.Semantic proximity Read ↗

Genetic characterisation of sarcomatoid carcinomas reveals multiple novel actionable mutations and identifies KRAS mutation as a biomarker of poor prognosis.Semantic proximity Read ↗

Analysis of molecular pathologic and clinical features of 36 patients with pulmonary sarcomatoid carcinomaSemantic proximity Read ↗

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable <i>MET</i> Gene MutationsSemantic proximity Read ↗

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.Semantic proximity Read ↗

Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.Semantic proximity Read ↗

The histopathological spectrum and molecular changes associated with KRAS G12C mutation in non-small cell lung carcinoma.Semantic proximity Read ↗

Genomic Landscape of Pulmonary Sarcomatoid Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.